Comparative Pharmacology
Head-to-head clinical analysis: NICLOCIDE versus STROMECTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICLOCIDE versus STROMECTOL.
NICLOCIDE vs STROMECTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits oxidative phosphorylation in cestodes, leading to paralysis and death of the parasite.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
2 g orally as a single dose, chewed thoroughly, for taeniasis; may repeat in 1 week for hymenolepiasis.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
None Documented
None Documented
The terminal elimination half-life of niclosamide is approximately 2-6 hours in patients with normal renal function; however, clinical efficacy against cestodes is prolonged due to its local action in the gastrointestinal tract.
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
Niclosamide is predominantly excreted in feces as unchanged drug and metabolites after oral administration. Renal excretion of metabolites accounts for less than 2% of an administered dose. Approximately 70% of the dose is recovered in feces within 2-3 days.
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic